TALIPEXOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N3S
Molecular Weight	209.311
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DHSSDEDRBUKTQY-UHFFFAOYSA-N

InChI=1S/C10H15N3S/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8/h2H,1,3-7H2,(H2,11,12)

HIDE SMILES / InChI

Molecular Formula	C10H15N3S
Molecular Weight	209.311
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	5.8 null [pKi]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	7.0 null [pKi]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.43 null [pKi]
Alpha-2b adrenergic receptor 27 Target ID: CHEMBL1942 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.09 null [pKi]
Alpha-2c adrenergic receptor 37 Target ID: CHEMBL1916 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.37 null [pKi]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	6.48 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic schizophrenia 6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8102551	Primary		Preclinical	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Analysis of ligand activation of alpha 2-adrenoceptor subtypes under conditions of equal G alpha protein stoichiometry.	2001 May	11383713
alpha(2)-adrenoceptor antagonist properties of OPC-28326, a novel selective peripheral vasodilator.	2001 Oct	11606316
Alpha2-adrenoceptor ligands inhibit alpha1-adrenoceptor-mediated contraction of isolated rat arteries.	2002 Aug	12570016
Influence of sildenafil on central dopamine-mediated behaviour in male rats.	2002 Feb 15	11895101
Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat.	2002 Mar	12047035
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.	2002 Nov	12388667
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.	2002 Nov	12388666
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.	2003	12732253
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors.	2003 Apr	12649387
Paraquat leads to dopaminergic neural vulnerability in organotypic midbrain culture.	2003 Aug	12871774
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.	2003 Aug 21	12873735
Effects of an alpha2-adrenoceptor agonist in nasal mucosa.	2003 Oct	15764068
Immunohistochemical and functional evidence for a noradrenergic regulation in the horse penile deep dorsal vein.	2004 Dec	15057259
Drug treatment of Parkinson's disease.	2004 Sep	22033779
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.	2007 Sep	18404453
Pharmacological modulation of dopaminergic brain activity and its reflection in spectral frequencies of the rat electropharmacogram.	2008	19142029
Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.	2008 Apr 30	18074382
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.	2008 Nov 19	18835264
Effective control of catatonia in Parkinson's disease by electroconvulsive therapy: a case report.	2009 Feb	19146631
Oxidative stress induction of DJ-1 protein in reactive astrocytes scavenges free radicals and reduces cell injury.	2009 Jan-Mar	20046643
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).	2009 Jun	19646081
Oxidative neurodegeneration is prevented by UCP0045037, an allosteric modulator for the reduced form of DJ-1, a wild-type of familial Parkinson's disease-linked PARK7.	2009 Nov 5	20087465
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.	2010 Dec	20673835
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.	2010 May	21209752
[Dopaminergic neuroprotection and reconstruction of neural network tiara].	2010 Oct	20930477

Patents

Sample Use Guides

In Vivo Use Guide

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:37:10 GMT 2023` Edited by `admin` on `Fri Dec 15 17:37:10 GMT 2023`
Record UNII	7AM2J46Z1Y
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALIPEXOLE

Official Name

English

6-ALLYL-2-AMINO-5,6,7,8-TETRAHYDRO-4H-THIAZOLO(4,5-D)AZEPINE

Systematic Name

English

talipexole [INN]

Common Name

English

Talipexole [WHO-DD]

Common Name

English

TALIPEXOLE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C66884